Ambrilia to Present at Canaccord Adams 28th Annual Global Growth Conference

MONTREAL, QUEBEC, Aug 05 (MARKET WIRE) --
Ambrilia Biopharma Inc. (TSX: AMB) today announced that Dr. Philippe
Calais, President and CEO, will present the Company and its projects at
the Canaccord Adams 28th Annual Global Growth Conference to be held in
Boston, August 12-14. This presentation will take place on Thursday,
August 14, at 8:00 am local time.

A live webcast of the presentation will be available on the Company's
website at www.ambrilia.com Investors' section, Webcasts and Conference
Calls. A webcast replay will be available approximately 1 hour after the
end of the presentation and will be accessible for 90 days.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (TSX: AMB) is a biotechnology company focused on
the discovery and development of novel treatments for viral diseases and
cancer. The Company's strategy aims to capitalize on its broad portfolio
and original expertise in virology. Ambrilia's product portfolio is
comprised of oncology and antiviral assets, including two new
formulations of existing peptides for cancer treatment, a therapeutic
peptide for prostate cancer, a targeted delivery technology for cancer,
an HIV protease inhibitor program (exclusive worldwide rights granted to
Merck & Co., Inc.) as well as HIV integrase and entry inhibitors,
Hepatitis C inhibitors and anti-Influenza A compounds. Ambrilia's head
office, research and development and manufacturing facilities are located
in Montreal with a regional office in France.

Contacts:
Ambrilia Biopharma Inc.
Julie M. Thibodeau, B.Sc., MBA
Director, Communications
514-751-2003 ext 235
jthibodeau@ambrilia.com / ir@ambrilia.com
www.ambrilia.com

Copyright 2008, Market Wire, All rights reserved.

-0-